UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For the
month of May, 2010
Commission
File Number: 000-51310
XTL Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
Kiryat
Weizmann Science Park
3
Hasapir Street, Building 3, PO Box 370
Rehovot 76100, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F X Form
40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
No X
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- N/A
Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated May 13, 2010 is
hereby incorporated by reference into the registration statements on Form F-3
(File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL
Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 23,
2007 , October 30, 2007 and August 15, 2008, respectively, and the registration
statements on Form S-8 (File No. 333-148085, File No. 333-148754 and File No.
333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and
Exchange Commission on December 14, 2007, January 18, 2008, and October 28,
2008, respectively.
XTL
Biopharmaceuticals Extends the
Completion
Date for the Bio-Gal Transaction
On April
26, 2010, XTL Biopharmaceuticals Ltd. (the “Company”) extended the completion
date for the Bio-Gal transaction to June 30, 2010. The remaining
conditions for the completion of the share exchange in the transaction remained
unchanged. The Bio-Gal transaction was included in the Company’s
annual financial statements published on the Tel Aviv Stock
Exchange. The Company’s annual financial statements were also
translated from Hebrew to English and filed on Form 6-K with the Securities
Exchange Commission on March 26, 2010.
The
Company is diligently seeking the fulfillment of the remaining
conditions.
Contact:
Investor
Relations, XTL Biopharmaceuticals Ltd.
Tel: +972
3 612 7011, Email: ir@xtlbio.com
Cautionary
Statement
Some of
the statements included in this Form 6-K may be forward-looking statements that
involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
XTL
BIOPHARMACEUTICALS LTD.
|
|
|
|
|
|
|
By:
|
/s/ David
Grossman |
|
|
|
David
Grossman
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|